Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

This study has been completed.

Sponsor:

Daewoong Pharmaceutical Co. LTD.

ClinicalTrials.gov Identifier:

NCT01557010

First Posted: March 19, 2012

Last Update Posted: February 21, 2014

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

20 Years to 80 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Male or Female subjects aged 20 to 80 years

Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).

Subjects must have pain present for > 3 months after healing of the acute herpes zoster skin rash.